Highlights
• AVITA Medical shares are trading 16.41% higher at AUD 1.49 during the 7 August 2026 session.
• First-quarter 2026 revenue increased 4% year on year to USD 19.3mn.
• AVITA reaffirmed full-year 2026 revenue guidance of USD 80mn to USD 85mn in May.
• The company has expanded its wound-care portfolio around RECELL, Cohealyx and PermeaDerm.
AVITA Medical, Inc. (ASX:AVH) is one of the more heavily traded names in this group during Friday's open session, with turnover above AUD 1.38mn and the shares up 16.41% at AUD 1.49. The move arrives at an important point in the company's 2026 reporting cycle, as the wound-care business works to show that recovering RECELL utilisation, newer products and tighter cost control can translate into steadier revenue growth and lower cash use.
Company Overview
AVITA Medical is a therapeutic acute wound-care company. Its core RECELL System enables healthcare professionals to prepare Spray-On Skin Cells from a small sample of a patient's own skin for the treatment of acute thermal burns and trauma wounds. In the United States, the company also markets PermeaDerm and Cohealyx as part of a broader wound-care portfolio.
Recent Developments
For the first quarter of 2026, AVITA reported total revenue of approximately USD 19.3mn, up 4% year on year and around 10% sequentially. The increase reflected contributions from Cohealyx and improved RECELL utilisation as reimbursement conditions normalised. Operating expenses fell 11% year on year to USD 24.5mn, while the net loss narrowed to USD 10.6mn from USD 13.9mn a year earlier. The company reaffirmed full-year 2026 revenue guidance of USD 80mn to USD 85mn.
Portfolio and Regulatory Progress
AVITA has continued broadening its commercial and regulatory footprint. In April 2026, it secured a 10-year BARDA agreement worth up to USD 25.5mn to support US burn emergency preparedness. The company also received regulatory clearance for RECELL GO in Australia and New Zealand and later highlighted the first UK clinical experience with the system. Positive interim Cohealyx study data reported in April showed a reduction in mean time to skin-grafting readiness in the study population.
What to Watch
The central issue for AVH is whether second-half execution supports the company's full-year revenue range while reducing cash use. RECELL utilisation trends, adoption of Cohealyx and PermeaDerm, reimbursement stability and operating expenses are likely to remain important metrics. Progress toward improved cash-flow performance is also material given the company's continuing net losses.
Risks
AVITA continues to report operating losses and remains dependent on successful commercial adoption across its product portfolio. Reimbursement changes, clinical uptake, product-mix effects on gross margin and cash requirements can influence performance. Healthcare regulatory and execution risks remain significant.






Please wait processing your request...